The synthesis of protected model dinucleoside (3',5')‐ O ‐aryl phosphorothioates, their separation into pure diastereomers, and their successful incorporation into oligonucleotides followed by stereospecific deprotection of the O ‐aryl phosphorothioate function with oximate ion (inversion) enables the preparation of chimeric PO/PS‐oligonucleotides with a predetermined sense of P ‐chirality at each internucleotide phosphorothioate position. The absolute configuration at the phosphorus of the internucleotide O ‐aryl phosphorothioate in “dimeric building blocks” has been assigned. The 3'‐terminal S P ‐phosphorothioate linkages effectively protect such chimeric constructs from degradation by human plasma exonuclease (© Wiley‐VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2005)
No takes yet. Share an insight, caveat, or question.
Woźniak et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: